Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic Hyperplasia - Concepedia

Concepedia

Publication | Closed Access

Efficacy and Safety of a New Prolonged Release Formulation of Alfuzosin 10 mg Once Daily versus Alfuzosin 2.5 mg Thrice Daily and Placebo in Patients with Symptomatic Benign Prostatic Hyperplasia

150

Citations

23

References

2000

Year

Philip Van Kerrebroeck, A Jardin, K.U. Laval, Paul Van Cangh

European Urology

UrologyMedicineBenign Prostatic HyperplasiaMg Thrice DailyPharmacotherapyProstatic DiseasePharmacologyAlfuzosin 10

References

	Year	Citations

Page 1